Lawmakers passed a budget that rejected Gov. Gavin Newsom’s proposal to save nearly $95 million by eliminating in-home support services for qualifying older, blind, and disabled immigrants lacking legal residency. Advocates say Newsom’s plan would have cost more in the long run. Newsom has not indicated whether he’ll veto.
If Indiana officials approve a proposed hospital merger in western Indiana in the coming months, the state will have its first hospital monopoly created by a “Certificate of Public Advantage.” Other such deals have resulted in government reports documenting diminished care in Tennessee and North Carolina.
The Supreme Court has dismissed a challenge to the FDA’s approval of the abortion pill mifepristone, ruling unanimously that the anti-abortion doctor group that filed the suit lacked standing. But abortion opponents are expected to pursue other strategies to ban or restrict the medication. Meanwhile, the Biden administration moves to stop the inclusion of medical debt on individual credit reports, and former President Donald Trump tries to claim credit for $35 insulin. Anna Edney of Bloomberg News, Rachana Pradhan of KFF Health News, and Emmarie Huetteman of KFF Health News join KFF Health News chief Washington correspondent Julie Rovner to discuss these stories and more. Also this week, Rovner interviews KFF president and CEO Drew Altman about KFF’s new “Health Policy 101” primer.
A medical residency program designed to train future primary care physicians in outpatient rather than hospital settings has proved an effective means to bring doctors to rural and underserved areas. But it hinges on unpredictable congressional funding.
The National Academies of Sciences, Engineering, and Medicine has proposed a more precise definition of long COVID-19.
Affordable Care Act (ACA) Marketplace plans rarely cover GLP-1 drugs approved solely for obesity treatment, according to a new KFF analysis of 2024 federal plan data. Wegovy, a drug that is approved for weight loss, is covered by just 1% of Marketplace…
Affordable Care Act (ACA) Marketplace plans rarely cover GLP-1 drugs approved solely for obesity treatment, according to a an analysis of 2024 federal plan data. Wegovy, a drug that is approved for weight loss, is covered by just 1% of Marketplace pres…
New data on substance use among young adults suggests that many former teen e-cigarette users are continuing the habit.
President Joe Biden is campaigning for reelection on his efforts to cut costs for Medicare patients at the pharmacy counter. But independent pharmacists say one strategy makes it unaffordable for them to keep some brand-name medicines in stock.
President Joe Biden is campaigning for reelection on his efforts to cut costs for Medicare patients at the pharmacy counter. But independent pharmacists say one strategy makes it unaffordable for them to keep some brand-name medicines in stock.
